Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

- Tezampanel Development Targeting Chronic Pain Conditions; Compound

Currently in Phase IIb Clinical Trial for Acute Migraine -

LA JOLLA, Calif., Aug. 27 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has initiated a Phase I multiple dose clinical trial to evaluate the safety, tolerability and pharmacokinetics of tezampanel given as a subcutaneous injection to healthy male and female volunteers once-daily for four consecutive days. Tezampanel, an AMPA/kainate (AK) receptor antagonist that selectively binds to certain AK receptors to potentially block the transmission of pain signals, has been administered in single doses to more than 300 patients and healthy adults. Data from this multiple dose trial will support the continued development of tezampanel for the treatment of migraine as well as allow TorreyPines to consider expanding the development of tezampanel into additional chronic pain conditions.

The double-blind, placebo-controlled, multiple-dose trial will be conducted at one center in the United States. Approximately 30 healthy male and female volunteers, between the ages of 21 and 55, will be enrolled in sequential, dose-escalating cohorts and receive once-daily subcutaneous doses of placebo or 40 mg, 70 mg or 100 mg of tezampanel for four consecutive days. These same dose strengths, given as a single dose subcutaneous injection, are currently being evaluated by TorreyPines in a Phase IIb clinical trial of tezampanel for acute migraine.

"We are pleased with our development progress for tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "Our Phase IIb trial in migraine has completed enrollment
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014   Easy Breathe , the fastest growing online ... Blog " - has received more than 4.5 million unique page ... are thrilled that so many people are finding our blog and ... Breathe. "We,re committed to making sleep apnea more widely known and ... about sleep apnea news , troubleshooting advice , and ...
(Date:8/20/2014)... YORK, Aug 20, 2014 Reportlinker.com announces ... in its catalogue: Global Patient Scales ... This report analyzes the worldwide markets for ... Product Segments: Floor Scales, Infant & Baby Scales, ... provides separate comprehensive analytics for the US, Canada, ...
(Date:8/20/2014)... SAN MARCOS, Texas , Aug. 20, 2014 ... purchase of five diverse sets of patent families ... and major innovation driver for Bayer AG of ... The patents acquired provide broad intellectual property ... achieved in economical high-volume quantum dot (QD) manufacturing. ...
Breaking Medicine Technology:Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4
... Inc. (OTC Bulletin Board: SCLR ) today ... and Drug Administration (FDA) identifying deficiencies regarding its Abbreviated ... The Company said the letter identified a number ... of the bioequivalence study submitted by SCOLR to support ...
... DIEGO, March 11, 2011 Conatus Pharmaceuticals Inc. today announced ... trial data of CTS-1027 for the treatment of hepatitis C ... Association for the Study of the Liver (EASL) to be ... 2011. Specifically, abstract 562 entitled: 24-WEEK TREATMENT WITH ...
Cached Medicine Technology:SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application 2Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March 2
(Date:8/21/2014)... August 21, 2014 While golfing in ... it hard to stay focused on his game due ... The constant whine, slapping and continual need to spray ... methods to stay protected from insects while golfing. He ... in the Financial Services/Investment Banking Industry, decided to change ...
(Date:8/21/2014)... Atlantic Information Services, Inc. (AIS) — industry-leading ... The AIS Report on Blue Cross & Blue Shield ... Association or its member companies) — is pleased to ... Management Insight Series. Bundled Payment Models: Bottom-Line Strategies ... — Horizon Healthcare Services, Inc. and Arkansas Blue Cross ...
(Date:8/21/2014)... San Diego, CA (PRWEB) August 21, 2014 ... website daily regarding all the latest information from the ... Solution . , The US FDA announced on August ... Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II), ... to the presence of particulate matter. , The ...
(Date:8/21/2014)... Sometimes you have to lose the life of your dreams ... to a Hundred: Finding My Purpose through My Pain,” Jason Roy, ... broken family, a childhood of gang violence and two life-altering car ... to be,” Roy said. “I didn’t give up on God when ... today of helping others overcome their trials.” , He said his ...
(Date:8/21/2014)... August 21, 2014 OpsAssure, the ... start-ups selected to participate in the Harbor Accelerator's ... mentorship, curriculum sessions and valuable resources.he Harbor’s goal ... the region. Each start-up selected for the program ... order to help businesses grow quickly, test markets ...
Breaking Medicine News(10 mins):Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:New AIS Report Highlights Two Case Studies of Bundled Payment Models 2Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2
... , , OAKLAND, Calif. , Jan. 13 ... have responded in less than one day to the call by ... assistance to residents of earthquake devastated Haiti —leading the ... support these efforts with donations of funds to support travel costs ...
... ... ... 2010 -- Connextions Inc. today announced the appointment of Kenneth A. Burdick ... with an outstanding record of management and fiscal performance with the nation’s most respected ...
... , KIRKLAND, Wash. , Jan. 13 Long term ... Lifetime Television,s Balancing Act show. Denise Gott , the featured expert, ... term care for our loved ones. "Three in four will eventually need ... (LTCFP), one of America,s most experienced long term care insurance ...
... , ... the trusted leader in acne treatment for 15 years, today ... revolutionized the treatment of acne now enhanced with exclusive micro-crystal ... to penetrate even clogged pores quickly is the first change ...
... surgeons say , WEDNESDAY, Jan. 13 (HealthDay News) -- ... coaxed a donor trachea to grow its own network ... for months in the recipient,s arm. , The innovative ... trachea (windpipe), but it did so without the need ...
... treatment, researcher says, , WEDNESDAY, Jan. 13 (HealthDay News) -- ... turn cancerous. , At issue is how mutations occur in ... Jan. 13 in Nature , researchers report that cancer-causing ... , "The bad news is that it is much easier ...
Cached Medicine News:Health News:National Conference Call Thursday for 1,500 RN Volunteers for Haiti Relief Effort 2Health News:Veteran Health Insurance Senior Executive Joins Connextions Inc. Board of Directors 2Health News:Veteran Health Insurance Senior Executive Joins Connextions Inc. Board of Directors 3Health News:Long Term Care Insurance Expert Featured on Lifetime Television's Balancing Act Show 2Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 2Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 3Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 4Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 5Health News:Transplanted Trachea Grows Own Blood Supply in Patient's Arm 2Health News:Transplanted Trachea Grows Own Blood Supply in Patient's Arm 3
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with teeth and 6 mm crisscross serrated tying surfaces. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Medicine Products: